Update on association between exposure to renin- angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there have been concerns about the association between exposure to renin-angiotensin-aldosterone system (RAAS) inhibitors and the risk and severity of COVID-19. Methods: We performed a case-control study that utilized up-to-date data on the South Korean population provided by the Korean National Health Insurance System. Of the 62,909 patients with hypertension or heart failure tested for COVID-19, there were 1,644 (2.6%) confirmed cases. After case-control matching, multivariable-adjusted conditional logistic regression analysis was performed. Results: Comparison between patients exposed to RAAS inhibitors and those not exposed to RAAS inhibitors revealed that the adjusted odds ratio (OR) and 95% confidence interval (CI) for COVID-19 infection and death were 0.981 (95% CI, 0.849 to 1.135) and 0.875 (95% CI, 0.548 to 1.396), respectively. Subgroup analysis for the major confounders, age and region of diagnosis, resulted in OR of 0.912 (95% CI, 0.751 to 1.108) and 0.942 (95% CI, 0.791 to 1.121), respectively. Conclusions: The present study demonstrated no evidence of association between RAAS inhibitor exposure and risk and severity of COVID-19.
Abstract
Background/Aims: Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there have been concerns about the association between exposure to renin-angiotensin-aldosterone system (RAAS) inhibitors and the risk and severity of COVID-19. Methods: We performed a case-control study that utilized up-to-date data on the South Korean population provided by the Korean National Health Insurance System. Of the 62,909 patients with hypertension or heart failure tested for COVID-19, there were 1,644 (2.6%) confirmed cases. After case-control matching, multivariable-adjusted conditional logistic regression analysis was performed. Results: Comparison between patients exposed to RAAS inhibitors and those not exposed to RAAS inhibitors revealed that the adjusted odds ratio (OR) and 95% confidence interval (CI) for COVID-19 infection and death were 0.981 (95% CI, 0.849 to 1.135) and 0.875 (95% CI, 0.548 to 1.396), respectively. Subgroup analysis for the major confounders, age and region of diagnosis, resulted in OR of 0.912 (95% CI, 0.751 to 1.108) and 0.942 (95% CI, 0.791 to 1.121), respectively. Conclusions: The present study demonstrated no evidence of association between RAAS inhibitor exposure and risk and severity of COVID-19.
참고문헌 (25)
- Kim M, "Weekly report on the COVID-19 situation in the Republic of Korea(As of June 20, 2020)", Public Health Wkly Rep, 13, pp.1859~1865 (2020)
- Zheng YY, "COVID-19 and the cardiovascular system", Nat Rev Cardiol, 17, pp.259~260 (2020)
- Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
- Hoffmann M, "SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
- Imai Y, "Angiotensin-converting enzyme 2 protects from severe acute lung failure", Nature, 436, pp.112~116 (2005)
- Danser AHJ, "Renin-angiotensin system blockers and the COVID-19 pandemic : at present there is no evidence to abandon renin-angiotensin system blockers", Hypertension, 75, pp.1382~1385 (2020)
- Vaduganathan M, "Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19", N Engl J
- Mancia G, "Renin-angiotensin-aldosterone system blockers and the risk of COVID-19", N Engl J Med, 382, pp.2431~2440 (2020)
- Li J, "Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019(COVID-19)infection in Wuhan, China", JAMA Cardiol, 5, pp.1~6 (2020)
- Reynolds HR, "Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19", N Engl J Med, 382, pp.2441~2448 (2020)
- Fernandez-Ruiz I, "RAAS inhibitors do not increase the risk of COVID-19", Nat Rev Cardiol, 17, pp.383~ (2020)
- Son M, "Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea", Hypertension, 76, pp.742~749 (2020)
- Kim JA, "Impact of visit-to-visit fasting plasma glucose variability on the development of type 2 diabetes : a nationwide population-based cohort study", Diabetes Care, 41, pp.2610~2616 (2018)
- Kim MK, "Effects of variability in blood pressure, glucose, and cholesterol concentrations, and body mass index on end-stage renal disease in the general population of Korea", J Clin Med, 8, pp.755~ (2019)
- Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future", Korean Circulation Journal, 46(5), pp.658~664 (2016), 대한심장학회
- Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
- Lee G, "Association of hemoglobin concentration and its change with cardiovascular and allcause mortality", J Am Heart Assoc, 7, pp.e007723~ (2018)
- Lee SR, "Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation", Stroke, 50, pp.2245~2249 (2019)
- Kim AM, "Regional variation of hospitalization rates for asthma in Korea : association with ambient carbon monoxide and health care supply", Int J Environ Res Public Health, 17, pp.1244~ (2020)
- 김유정, "Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study", Journal of Korean Medical Science, 34(2), pp.1~10 (2019), 대한의학회
- de Groot V, "How to measure comorbidity. A critical review of available methods", J Clin Epidemiol, 56, pp.221~229 (2003)
- Iaccarino G, "Age and multimorbidity predict death among COVID-19 patients : results of the SARS-RAS study of the Italian Society of Hypertension", Hypertension, 76, pp.366~372 (2020)
- Jung SY, "Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea : a nationwide population-based cohort study", Clin Infect Dis, pp.ciaa624~ (2020)
- Fang L, "Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?", Lancet Respir Med, 8, pp.e21~ (2020)
- Korean Society Hypertension (KSH), "Korea hypertension fact sheet 2018", Clin Hypertens, 24, pp.13~ (2018)